An interventional study of Percutaneous cholecystostomy and EUS-guided gallbladder drainage in Acute Cholecystitis, sponsored by Orlando Health, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.
Sponsored by Orlando Health, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Cholecystitis, Acute with a site in United States — 5 open to participants now, 5 under way, none of them phase 3. Cholecystitis, Acute · United States.
Among the 17 studies in Cholecystitis, Acute with a site in United States, this one is the 3rd largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2026, is one of 9 with no phase, and was the 15th registered.
140 studies on the registry are indexed under Cholecystitis, Acute; 30 are open to participants now.
Browse Cholecystitis, Acute studies →5 of the 17 studies in Cholecystitis, Acute with a site in United States are open now. Recruiting first, the newest first:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in United States, Belgium, Germany and 2 more countries
Ages 18+
WellSpan Health · Sites in United States
Ages 18+
Activ Surgical · Sites in United States
Ages 18+ · Healthy volunteers
European Society for Trauma and Emergency Surgery · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 21 Cholecystitis, Acute studies recruiting now, 17 (81%) set no upper age limit and 2 (10%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 110 is above the median of 90 across 84 interventional studies indexed under Cholecystitis, Acute.
Median enrollment 49 across the 10 interventional studies, 116 across the 7 observational. Of the 10 that completed or were terminated, 3 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 17 have an industry lead sponsor. The 10 most frequent:
Orlando Health, Inc. is the lead sponsor of 28 studies on the registry; 10 are open to participants now.
Orlando Health, Inc. has 1 study filed under Cholecystitis, Acute — fewer than ten, so there is no comparison to draw.
1 of the studies in Cholecystitis, Acute with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07568080European Society for Trauma and Emergency SurgerySnapChole: An International, Time-Bound Prospective Platform Study of Management Strategies and Outcomes in Acute Calculous Cholecystitis | 2027-08-01 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Cholecystitis, Acute with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized trial of patients with acute calculous cholecystitis who are never-surgery candidates. Patients will be randomized to one of two treatment groups, percutaneous cholecystostomy or endoscopic ultrasound-guided drainage. The aim of the study is to compare between these two treatment methods, the treatment outcomes and quality of life over a follow-up duration of 36 months.
Acute calculous cholecystitis (ACC) is characterized by an inflammatory condition involving the gallbladder wall, most often caused by an obstruction at the infundibulum or cystic duct, with less than 10% of cases provoked by other causes.
Surgical cholecystectomy (SC), especially by laparoscopic assistance, is considered the gold standard approach for the treatment of ACC. However, some patients due to high frailty, multiple comorbidities, and clinically significant organ failure are considered suboptimal or "unfit" candidates for surgery. Therefore, less invasive approaches have been developed for this challenging population.
Percutaneous choleystostomy (PC) has been traditionally considered the first alternative in patients who are not considered for surgery, as it is a less invasive approach with lower rates of complications compared to SC. The procedure is considered technically easy for experienced interventional radiologists and is based on the insertion of a percutaneous catheter in the gallbladder under fluoroscopic assistance after an ultrasound-guided puncture with an 18-gauge needle. Nevertheless, like any other procedure, PC is not exempt from complications, such as bleeding, pneumothorax, peritonitis, injury to adjacent organs, pain at the site of insertion, catheter dislodgement, and risk for recurrent cholecystitis upon removal of the catheter.
Endoscopic ultrasound (EUS)-guided gallbladder drainage (EUS-GBD) has been described as another minimally invasive option for these patients. Under endoscopic ultrasound-guidance, a lumen-apposing metal stent is placed within the gallbladder lumen from the stomach or the duodenum (EUS-GBD), thus allowing internal drainage. EUS-GBD appears to have some benefits over PC, since the latter is typically associated with patient's discomfort and pain at the site of insertion, and carries inherent disadvantages associated with external drainage.
The management of ACC in patients who are not surgical candidates is complex. These patients carry a high risk of peri-cholecystectomy and post-cholecystectomy complications and a mortality rate of up to 19%. The initial management of patients who are not surgical candidates consists of antibiotic therapy and minimally invasive procedures for adequate gallbladder drainage. These procedures include PC and endoscopy-guided gallbladder drainage. Tokyo Guidelines-2018 (TG-18) recommend PC as the standard drainage method for surgically high-risk patients with AC. World Society of Emergency Surgery 2020 guidelines recommend considering endoscopic transpapillary gallbladder drainage (ET-GBD) or EUS-GBD as an alternative to PC in high-volume centers when performed by skilled endoscopists. There is a lumen-apposing metal stent (LAMS), which was recently approved by the Food and Drug Administration (FDA) for EUS-GBD in poor surgical candidates.
In a prior study (DRAC 1) that compared PC versus EUS-GBD in high-risk patients with ACC, EUS-GBD was associated with significantly fewer adverse events, readmissions and recurrent cholecystitis. However, the follow-up duration was only 12 months, which is a very short timeframe to reliably compare long-term outcomes between modalities. This is particularly relevant as nearly 45% of patients who do not receive a cholecystectomy die within 825 days of an attack of ACC. Also, health-related quality of life and treatment costs were not assessed in DRAC 1. Finally, the primary outcome in the DRAC 1 trial was only a single measure - adverse events. The burden of ACC and the impact of treatment is more accurately measured using a composite endpoint encompassing readmissions and reinterventions in addition to adverse events.
We hypothesize that by performing EUS-GBD as the first-line therapy in never-surgery patients presenting with ACC, the rates of procedural reinterventions, readmissions, and disease or procedure-related adverse events can be reduced as compared to patents undergoing percutaneous cholecystostomy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with acute calculous cholecystitis who are never-surgery candidates undergoing percutaneous cholecystostomy tube placement
Procedure: Percutaneous cholecystostomy
Patients with acute calculous cholecystitis who are never-surgery candidates, undergoing EUS-guided gallbladder drainage
Procedure: EUS-guided gallbladder drainage
Percutaneous cholecystostomy tube placement by interventional radiology
EUS-guided gallbladder drainage using metal stent
Composite endpoint of 1) procedure-related adverse events, 2) reintervention for disease recurrence or procedure-related adverse events, and/or 3) readmission due to underlying disease or procedure-related adverse events
A composite endpoint of 1) procedure-related adverse events, 2) reintervention for disease recurrence or procedure-related adverse events, and/or 3) readmission due to underlying disease or procedure-related adverse events, from index procedure to 36 months post-index intervention.
Time frame: 36 months
Mortality
Rate of mortality at 30 days post-index intervention due to underlying disease.
Time frame: 30 days
Procedure-related adverse events
Rate of procedure-related adverse events, defined as adverse events resulting from the endoscopic or radiological procedures performed. Procedure-related adverse events will be graded according to Clavien-Dindo classification.
Time frame: 36 months
Disease-related adverse events
Rate of disease-related adverse events, defined as adverse events resulting from underlying acute cholecystitis (such as gallbladder perforation, sepsis).
Time frame: 36 months
New onset single and multiple organ failure.
Rate of new onset single and multiple organ failure.
Time frame: 36 months
New onset systemic dysfunction.
Rate of new onset systemic dysfunction.
Time frame: 36 months
Intraabdominal bleeding.
Rate of intraabdominal bleeding.
Time frame: 36 months
Leakage of bile from the gallbladder or the biliary tract.
Rate of leakage of bile from the gallbladder or the biliary tract.
Time frame: 36 months
Perforation of a visceral organ requiring interventional procedure.
Rate of perforation of a visceral organ requiring interventional procedure.
Time frame: 36 months
Stent or percutaneous catheter-related complications
Rate of stent or percutaneous catheter-related complications, such as percutaneous catheter (cholecystostomy tube) insertion site infection, percutaneous catheter dislodgement.
Time frame: 36 months
Disease recurrence
Rate of disease recurrence, which includes acute cholecystitis or biliary colic.
Time frame: 36 months
Need for reintervention
Rate of reintervention (reintervention defined as any unplanned endoscopic, radiological or surgical intervention performed following index intervention due to recurrent or persistent symptoms or acute cholecystitis).
Time frame: 36 months
Total number of reinterventions performed
Total number of reinterventions performed, including endoscopic, surgical and radiological interventions.
Time frame: 36 months
Length of hospitalization
Length of hospitalization, including length of ICU stay.
Time frame: 36 months
Readmissions
Rate of readmissions due to symptoms from underlying disease or procedure-related adverse events.
Time frame: 36 months
New onset SIRS at 24, 48 and 72 hours, post-index intervention.
Rate of New onset SIRS at 24, 48 and 72 hours, post-index intervention.
Time frame: 72 hours
Resolution and improvement of SIRS at 24, 48 and 72 hours, post-index intervention.
Rate of Resolution and improvement of SIRS at 24, 48 and 72 hours, post-index intervention.
Time frame: 72 hours
Technical success
Rate of Technical success, defined as the successful placement of metal stent or percutaneous catheter.
Time frame: 36 months
Clinical success
Rate of Clinical success, defined as resolution of symptoms and normalization of laboratory parameters prior to hospital discharge after index intervention.
Time frame: 36 months
Health-related quality of life (HRQoL) scores
Health-related quality of life (HRQoL) scores as assessed by the Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36) at randomization, discharge, 1 month, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months and 36 months after index intervention.
Time frame: 36 months
Overall treatment costs from index intervention until hospital discharge.
Overall treatment costs from index intervention until hospital discharge. All relevant costs pertaining to treatment will be taken into consideration - procedure costs, inpatient hospital stay from date of procedure to discharge, medications, materials, anesthesia, pharmacy and imaging studies.
Time frame: 36 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Jun 2032, 71 months later.
Of 43 non-industry interventional studies with no phase under Cholecystitis, Acute, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's planned 71 months is above that.
Counting every sponsor, half of 46 studies reached it within 20 months; a quarter within 9 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Orlando Health, Inc.